More than one third of the drugs used today act at G protein-coupled receptors (GPCRs). GPCRs and their downstream signalling cascades are the

basis for current pharmacotherapeutic concepts. More drugs interfere

with GPCRs than with any other protein or cell structure. New insights into previously largely unknown non-canonical regulatory mecha-

nisms of G-protein signalling pathways open up new ap-

proaches for promising pharmacotherapeutic interven-

tions. Non-canonical G-protein signalling in particular is

predicted to have great potential for precision medicine.

Our RTG aims to uncover the underlying mechanisms,

functions and consequences of non-canonical G protein

signaling and to develop novel therapies.